These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8267111)

  • 1. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.
    Flicker C; Ferris SH; Kalkstein D; Serby M
    Am J Psychiatry; 1994 Jan; 151(1):126-9. PubMed ID: 8267111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment trial of oxiracetam in Alzheimer's disease.
    Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
    Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
    Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
    Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter trial of naloxone in Alzheimer's disease.
    Henderson VW; Roberts E; Wimer C; Bardolph EL; Chui HC; Damasio AR; Eslinger PJ; Folstein MF; Schneider LS; Teng EL
    Ann Neurol; 1989 Apr; 25(4):404-6. PubMed ID: 2653175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
    Tsai GE; Falk WE; Gunther J; Coyle JT
    Am J Psychiatry; 1999 Mar; 156(3):467-9. PubMed ID: 10080566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy.
    Ala T; Romero S; Knight F; Feldt K; Frey WH
    Arch Neurol; 1990 Oct; 47(10):1126-30. PubMed ID: 2222246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clipp EC; Moore MJ
    Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
    Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
    Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.
    Harbaugh RE; Reeder TM; Senter HJ; Knopman DS; Baskin DS; Pirozzolo F; Chui HC; Shetter AG; Bakay RA; Leblanc R
    J Neurosurg; 1989 Oct; 71(4):481-6. PubMed ID: 2571689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.